SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Legend Biotech Corporation
(Name of Issuer)
(Title of Class of Securities)
December 31, 2022
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|CUSIP No. 52490G102||13G/A||Page 2 of 4|
NAMES OF REPORTING PERSONS
GenScript Biotech Corporation
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐ (b) ☐
SEC USE ONLY
CITIZENSHIP OR PLACE OF ORGANIZATION
SOLE VOTING POWER
SHARED VOTING POWER
SOLE DISPOSITIVE POWER
SHARED DISPOSITIVE POWER
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
TYPE OF REPORTING PERSON
Represents the sum of (i) 169,680,000 ordinary shares held by GenScript Biotech Corporation (GenScript) before the Issuers initial public offering completed in June 2020 (the IPO), (ii) 1,043,478 ordinary shares issued to GenScript in a private placement transaction that closed concurrently with the IPO, which was reduced by 725,922 ordinary shares that were distributed by GenScript to its shareholders in connection with the IPO to effect an assured entitlement distribution pursuant to the rules of the Hong Kong Stock Exchange and (iii) 2,250,000 American Depositary Shares that were purchased in connection with the Issuers follow-on offering completed in December 2021.
This percentage is calculated based on 334,805,584 ordinary shares issued and outstanding as of September 13, 2022, as reported in the Issuers Proxy Statement furnished to the Securities and Exchange Commission under the cover of a Form 6-K on September 16, 2022.
|CUSIP No. 52490G102||13G/A||Page 3 of 4|
Item 1(a). Name of Issuer:
Legend Biotech Corporation (the Issuer)
Item 1(b). Address of Issuers Principal Executive Officers:
The Issuers principal executive office is located at 2101 Cottontail Lane, Somerset, New Jersey 08873.
Item 2(a). Name of Person Filing:
GenScript Biotech Corporation
Item 2(b). Address or Principal Business Office or, if None, Residence:
The headquarter and principal business office for the Reporting Person in the Peoples Republic of China is No. 28, Yongxi Road, Jiangning Science Park, Nanjing, Jiangsu Province, China 211100.
Item 2(c). Citizenship:
See Item 4 of the cover page.
Item 2(d). Title of Class of Securities:
American Depositary Shares, each representing two ordinary shares, par value US$0.0001 per share.
Item 2(e). CUSIP No.:
Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c)
Item 4. Ownership.
The percentage set forth in this Schedule 13G/A is calculated based upon an aggregate of 334,805,584 Ordinary Shares outstanding as of September 13, 2022, as reported in the Issuers Proxy Statement furnished to the Securities and Exchange Commission under the cover of a Form 6-K on September 16, 2022.
The information required by Items 4(a)(c) is set forth in Rows 511 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5. Ownership of 5 Percent or Less of a Class.
Item 6. Ownership of More than 5 Percent on Behalf of Another Person.
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Item 8. Identification and Classification of Members of the Group.
Item 9. Notice of Dissolution of Group.
|Item 10.|| |
|CUSIP No. 52490G102||13G/A||Page 4 of 4|
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|Date: February 13, 2023||GenScript Biotech Corporation|
|Name: Jiange Meng|